NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $0.94 -0.02 (-2.08%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Assertio Stock (NASDAQ:ASRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assertio alerts:Sign Up Key Stats Today's Range$0.93▼$0.9950-Day Range$0.81▼$1.3552-Week Range$0.73▼$1.80Volume700,073 shsAverage Volume924,267 shsMarket Capitalization$89.83 millionP/E RatioN/ADividend YieldN/APrice Target$3.25Consensus RatingBuy Company OverviewAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Assertio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks65th Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 65% of companies evaluated by MarketBeat, and ranked 386th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has received no research coverage in the past 90 days.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.38% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.38% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently decreased by 1.77%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment1.03 News SentimentAssertio has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Assertio this week, compared to 3 articles on an average week.Search Interest14 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows11 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,950.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesInsider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires 75,000 Shares of StockNovember 20 at 6:24 AM | insidertrades.comAssertio (NASDAQ:ASRT) Rating Increased to Buy at StockNews.comNovember 17, 2024 | americanbankingnews.comShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.November 23, 2024 | Brownstone Research (Ad)Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at AssertioNovember 15, 2024 | tmcnet.comAssertio Therapeutics (ASRT) Receives a Buy from Lake StreetNovember 13, 2024 | markets.businessinsider.comAssertio Holdings price target lowered to $2.15 from $2.75 at Alliance GlobalNovember 13, 2024 | markets.businessinsider.comAssertio calls short-seller claims about accounting practices ‘false, baseless’November 12, 2024 | markets.businessinsider.comAssertio stock gains amid Q3 earnings, clash with activist investorNovember 12, 2024 | msn.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT stock has decreased by 12.1% and is now trading at $0.9408. View the best growth stocks for 2024 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) issued its quarterly earnings results on Monday, November, 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The company earned $29.20 million during the quarter, compared to the consensus estimate of $29.29 million. Assertio had a positive trailing twelve-month return on equity of 3.79% and a negative net margin of 54.46%. Who are Assertio's major shareholders? Top institutional shareholders of Assertio include Geode Capital Management LLC (1.13%), Empowered Funds LLC (0.45%), Palumbo Wealth Management LLC (0.20%) and XTX Topco Ltd (0.18%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, Jeff L Vacirca, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID). Company Calendar Last Earnings11/11/2024Today11/23/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$3.25 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+245.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-54.46% Pretax Margin-33.94% Return on Equity3.79% Return on Assets1.81% Debt Debt-to-Equity Ratio0.30 Current Ratio2.01 Quick Ratio1.57 Sales & Book Value Annual Sales$152.07 million Price / Sales0.59 Cash Flow$0.71 per share Price / Cash Flow1.33 Book Value$1.37 per share Price / Book0.69Miscellaneous Outstanding Shares95,480,000Free Float92,423,000Market Cap$89.83 million OptionableOptionable Beta0.83 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ASRT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.